Literature DB >> 2331226

Radioimmunotherapy of human colon cancer in nude mice.

R R Buras1, B G Beatty, L E Williams, P M Wanek, J B Harris, L R Hill, J D Beatty.   

Abstract

Nude mice bearing subcutaneous human colon cancer xenografts (LS174T) were treated with 120 microCi of yttrium 90-labeled anti-carcinoembryonic antigen monoclonal antibodies (specific therapy), 120 microCi of 90Y-labeled anti-melanoma monoclonal antibodies (nonspecific therapy), or phosphate-buffered saline solution (no treatment control). Mean (+/- SD) tumor growth rates (percent increase per day) over the first 30 days of the study were as follows: 0.6% +/- 0.2% per day (specific therapy); 17.7% +/- 5.7% per day (nonspecific therapy); and 30.5% +/- 4.2% per day (control). In all three groups, tumors over 1 g had similar doubling times (5.74 +/- 0.71 d). Specific therapy caused a lag in tumor growth corresponding to a 3-logarithm cell kill. Estimated tumor dose of radiation obtained by tissue analysis was 34 and 14 Gy for specific and nonspecific therapy, respectively. In conclusion, 120 microCi of 90Y-labeled anti-carcinoembryonic antigen monoclonal antibodies was effective in suppressing growth of human colon cancer xenografts. Clinical studies with this preparation are recommended.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2331226     DOI: 10.1001/archsurg.1990.01410170108023

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  2 in total

1.  Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.

Authors:  J M Connett; C J Anderson; L W Guo; S W Schwarz; K R Zinn; B E Rogers; B A Siegel; G W Philpott; M J Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Coexpression of carcinoembryonic antigen and E-cadherin in colorectal adenocarcinoma with liver metastasis.

Authors:  Jin C Kim; Seon A Roh; Hee C Kim; Kum H Koo; Young K Cho; Chang S Yu; Young M Kwon; Jung S Kim
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.